The procalcitonin (PCT) assay market size is projected to be worth USD 280.6 million in 2023. The market is likely to surpass USD 512.9 million by 2033 at a CAGR of 6.2% during the forecast period.
Growing lung cancer incidences is aiding the market growth. The PCT assay market has seen significant growth in recent years due to the increasing awareness about the importance of early and accurate diagnosis of bacterial infections The Procalcitonin (PCT) assay refers to the market for diagnostic tests that measure the levels of procalcitonin in the bloodstream. Procalcitonin is a precursor protein to the hormone calcitonin and is produced in response to bacterial infections.
Other Drivers Propelling the Demand for Procalcitonin (PCT) Assay Market include:
Challenges for Companies /Manufacturers in the Procalcitonin (PCT) Assay Market:
Opportunities in the Procalcitonin (PCT) Assay Market Industry:
Latest Trends in the Procalcitonin (PCT) Assay Market:
| Attributes | Details |
|---|---|
| Procalcitonin (PCT) Assay Market Size (2023) | USD 280.6 million |
| Procalcitonin (PCT) Assay Market Projected Size (2033) | USD 512.9 million |
| Value CAGR (2023 to 2033) | 6.2% |
Exclusive Offer: 30% Off on Regional Reports
Get a free sample report and customize your regions for a 30% discount on your regional report!
From 2012 to 2022, the global procalcitonin (PCT) assay market experienced a CAGR of 3.0%, reaching a market size of USD 280.6 million in 2023.
The global procalcitonin (PCT) assay market witnessed steady growth in the past and is expected to continue to develop at a significant pace due to their increasing demand in non-hospital settings, such as primary care clinics and outpatient facilities. The increasing availability of PCT testing options, including point-of-care devices, facilitates broader access to PCT testing and supports early diagnosis and appropriate management of bacterial infections in various healthcare settings.
With the rising concern of antibiotic resistance, there is an increased emphasis on antibiotic stewardship programs. PCT assays play a vital role in these programs by assisting clinicians in determining the need for antibiotic therapy, optimizing treatment duration, and monitoring response to treatment. This is also leading to enhanced integration of PCT testing into antibiotic stewardship protocols.
Future Forecast for Procalcitonin (PCT) Assay Market Industry:
Looking ahead, the global procalcitonin (PCT) assay market is expected to rise at a CAGR of 6.2% from 2023 to 2033. During the forecast period, the market size is expected to reach USD 512.9 million by 2033.
PCT is increasingly being used as part of biomarker panels or algorithms to improve the accuracy of infection diagnosis and prognosis. Combining PCT with other biomarkers, such as C-reactive protein (CRP) or proadrenomedullin (MR-proADM), can provide a more comprehensive assessment of the severity and course of an infection, this could likely increase the sales of PCT assays in the coming times.
Collaboration between diagnostic companies, assay manufacturers, and healthcare providers is becoming more prevalent. Partnerships and collaborations among manufactures will combine expertise, resources, and technologies to develop innovative PCT assays, improve accessibility, and expand market reach. These partnerships can lead to the development of integrated diagnostic solutions and improved patient care.
| Country | The United States |
|---|---|
| Market Size (USD Million) by End of Forecast Period (2033) | USD 202.0 million |
| CAGR % 2023 to End of Forecast (2033) | 7.3% |
The procalcitonin (PCT) assay market in the United States is expected to reach a market size of USD 202.0 million by 2033, expanding at a CAGR of 7.3%. The United States has been experiencing a rising incidence of bacterial infections, including community-acquired pneumonia, sepsis, and urinary tract infections. This has heightened the need for accurate and timely diagnosis to guide appropriate treatment decisions. PCT assays offer valuable insights for differentiating bacterial from viral infections, aiding in the diagnosis and management of these conditions.
| Country | The United Kingdom |
|---|---|
| Market Size (USD Million) by End of Forecast Period (2033) | USD 26.4 million |
| CAGR % 2023 to End of Forecast (2033) | 8.3% |
The procalcitonin (PCT) assay market in the United Kingdom is expected to reach a market value of USD 26.4 million, expanding at a CAGR of 8.3% during the forecast period. The availability of favorable reimbursement policies for PCT testing has played a role in the market growth of PCT assays in the UK. Reimbursement coverage by public and private payers incentivizes healthcare providers to adopt and utilize PCT assays, ensuring proper compensation for the testing services provided.
| Country | China |
|---|---|
| Market Size (USD Million) by End of Forecast Period (2033) | USD 62.7 million |
| CAGR % 2023 to End of Forecast (2033) | 9.1% |
The procalcitonin (PCT) assay market in China is anticipated to reach a market size of USD 62.7 million by the end of 2033, growing at a CAGR of 9.1% throughout the forecast period. There has been a significant increase in awareness among healthcare professionals in China about the clinical utility and benefits of PCT testing. Educational initiatives, conferences, and scientific publications have contributed to the dissemination of knowledge regarding PCT assays and their role in infection management. This improved awareness has led to increased demand for PCT assays in the country.
| Country | Japan |
|---|---|
| Market Size (USD Million) by End of Forecast Period (2033) | USD 20.8 million |
| CAGR % 2023 to End of Forecast (2033) | 6.7% |
The procalcitonin (PCT) assay market in Japan is estimated to reach a market size of USD 20.8 million by 2033, expected to thrive at a CAGR of 6.7%. Technological advancements have improved the accessibility and efficiency of PCT assays. Automated platforms, rapid testing options, and point-of-care devices have made PCT testing more convenient and streamlined in various healthcare settings. These advancements have facilitated the integration of PCT assays into routine clinical practice, leading to their surge in the Japan.
| Country | South Korea |
|---|---|
| Market Size (USD Million) by End of Forecast Period (2033) | USD 13.9 million |
| CAGR % 2023 to End of Forecast (2033) | 6.0% |
The procalcitonin (PCT) assay market in South Korea is expected to reach a market size of USD 13.9 million, expanding at a CAGR of 6.0% during the forecast period. South Korea has a robust healthcare infrastructure, including hospitals, clinics, and diagnostic laboratories. This infrastructure supports the implementation and utilization of PCT assays in routine practice. The presence of well-equipped healthcare facilities and the availability of trained personnel contribute to the increased demand for PCT assays in the country.
Serum sample dominated the procalcitonin (PCT) assay market with a market share of 34.2% in 2022. Collecting serum samples is a routine and minimally invasive procedure. Blood samples can be easily obtained through venipuncture and processed to separate serum and plasma from other blood components. This simplicity and familiarity make serum a convenient sample type for PCT assay testing.
Based on products, test kits have dominated the category withholding the significant share of the market at around 68.7% at the end of 2022. Test kits for PCT assays are readily available in the market from multiple manufacturers.
This wide availability ensures that laboratories and healthcare facilities have access to a variety of options, allowing them to select the test kit that best fits their specific requirements in terms of performance, cost, and workflow compatibility.
By purpose, clinical use segment is expected to continue leading the market over a CAGR of 6.0% throughout the projected timeframe. PCT assays have proven clinical utility in the diagnosis of bacterial infections, especially severe infections such as sepsis.
PCT levels in the bloodstream rise significantly in response to bacterial infections, making it a valuable biomarker for differentiating bacterial from viral infections. This diagnostic value has led to the widespread adoption of PCT assays in clinical practice for guiding antibiotic therapy and supporting clinical decision-making.
The hospitals have led the procalcitonin (PCT) assay market as the leading end user with the market share of 36.7% in 2022. Hospitals are primary providers of acute care, dealing with a wide range of patients, including those with severe infections, sepsis, and other critical conditions.
PCT assays have significant clinical utility in these settings, aiding in the diagnosis, monitoring, and management of bacterial infections. Hospitals rely on PCT assays to support clinical decision-making, guide antibiotic therapy, and assess patient prognosis in these acute care scenarios.
By employing these strategies, key players in the PCT assay market can enhance their competitiveness, differentiate their offerings, and maintain a strong market presence. Continuous innovation, strategic partnerships, effective marketing, and customer-centric approaches are crucial for sustained success in this competitive industry.
Key Strategies Used by the Participants
Product Innovation
Key players continuously invest in research and development to introduce innovative PCT assay products. They strive to develop assays with improved sensitivity, specificity, accuracy, and ease of use.
Strategic Partnerships and Collaborations
Key players often form strategic partnerships and collaborations with other companies, research institutions, and healthcare organizations. These partnerships can lead to knowledge sharing, joint product development, and expanded market reach.
Expansion into Emerging Markets
Expanding into emerging markets with growing healthcare infrastructure and rising demand for PCT assays allows companies to tap into new opportunities and gain a competitive edge.
Mergers and Acquisitions
Companies in the market may engage in mergers or acquisitions to streamline their product portfolio, obtain new technologies, enter new market niches, and gain access to novel products or intellectual property.
Check Free Sample Report & Save 40%!
Select your niche segments and personalize your insights for smart savings. Cut costs now!
Key Developments in the Procalcitonin (PCT) Assay Market:
The global procalcitonin (PCT) assay market is expected to reach a valuation of USD 280.6 million by 2023.
The procalcitonin (PCT) assay market demand is set to expand by 6.2% during the assessment period.
The test kits segment is projected to hold the dominant share of the market.
The market is predicted to exceed USD 512.9 million by 2033.
The North America offers key opportunities for new entrants in the procalcitonin (PCT) assay market.
Explore In-vitro Diagnostics Devices Insights
View Reports
Procalcitonin (PCT) Assay Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
